Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy

Vijay Bhooshon Kumar; Himadri Medhi; Zhang Yong; Pradip Paik

doi:10.1016/j.nano.2015.10.007

Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy

Vijay Bhooshon Kumar, Himadri Medhi, Zhang Yong, Pradip Paik^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

21 Citations (Scopus)

Abstract

In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells. © 2015 Elsevier Inc.

Original language	English
Pages (from-to)	579-588
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.nano.2015.10.007
Publication status	Published - 1 Apr 2016
Externally published	Yes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

Research Keywords

Cancer therapy
Hollow-mesoporous-PCL
Nanocapsules
Nanoformulation
SiRNA-silencing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access Output

10.1016/j.nano.2015.10.007

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{abadfe03c38f4ddf824820c70c3c5650,

title = "Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy",

abstract = "In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells. {\textcopyright} 2015 Elsevier Inc.",

keywords = "Cancer therapy, Hollow-mesoporous-PCL, Nanocapsules, Nanoformulation, SiRNA-silencing",

author = "Kumar, {Vijay Bhooshon} and Himadri Medhi and Zhang Yong and Pradip Paik",

note = "Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected]. ",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.nano.2015.10.007",

language = "English",

volume = "12",

pages = "579--588",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy

AU - Kumar, Vijay Bhooshon

AU - Medhi, Himadri

AU - Yong, Zhang

AU - Paik, Pradip

N1 - Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells. © 2015 Elsevier Inc.

AB - In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells. © 2015 Elsevier Inc.

KW - Cancer therapy

KW - Hollow-mesoporous-PCL

KW - Nanocapsules

KW - Nanoformulation

KW - SiRNA-silencing

UR - http://www.scopus.com/inward/record.url?scp=84959422277&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-84959422277&origin=recordpage

U2 - 10.1016/j.nano.2015.10.007

DO - 10.1016/j.nano.2015.10.007

M3 - RGC 21 - Publication in refereed journal

C2 - 26554393

SN - 1549-9634

VL - 12

SP - 579

EP - 588

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

IS - 3

ER -

Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy

Abstract

Bibliographical note

Research Keywords

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this